StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Consolidated revenues — Europe by Year

Consolidated revenues — Europe ($M) ($M)

Gilead Sciences Consolidated revenues — Europe: $5,064M in FY2025, up 9.3% from a year earlier.

Latest, FY2025
5,064
Period ended Dec 31, 2025
Change on a year earlier
+9.3%
4,634 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Geographic Information.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConsolidated revenues — Europe ($M) ($M)Year on yearSource
FY2025Dec 31, 20255,064+9.3%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 20244,634+7.5%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20234,310-3.6%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 20224,469-8.3%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 20214,874+17.9%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 20204,135+8.5%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20193,811-4.9%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 20184,006-24.6%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 20175,311-16.6%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 20166,365-15.4%Form 10-K (filed 2019-02-26) ↗
FY2015Dec 31, 20157,528+38.3%Form 10-K (filed 2018-02-27) ↗
FY2014Dec 31, 20145,442–Form 10-K (filed 2017-02-27) ↗

Cite this data

StockData. (2026). Gilead Sciences Consolidated revenues — Europe ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/geo-rev-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.